ATE224712T1 - Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen - Google Patents

Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen

Info

Publication number
ATE224712T1
ATE224712T1 AT94916710T AT94916710T ATE224712T1 AT E224712 T1 ATE224712 T1 AT E224712T1 AT 94916710 T AT94916710 T AT 94916710T AT 94916710 T AT94916710 T AT 94916710T AT E224712 T1 ATE224712 T1 AT E224712T1
Authority
AT
Austria
Prior art keywords
fibrotic
injuries
repairing
compositions
methods
Prior art date
Application number
AT94916710T
Other languages
English (en)
Inventor
Solomon B Margolin
Original Assignee
Solomon B Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solomon B Margolin filed Critical Solomon B Margolin
Application granted granted Critical
Publication of ATE224712T1 publication Critical patent/ATE224712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
AT94916710T 1993-05-07 1994-05-09 Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen ATE224712T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5921493A 1993-05-07 1993-05-07
US6483193A 1993-05-19 1993-05-19
PCT/US1994/005156 WO1994026249A1 (en) 1993-05-07 1994-05-09 Compositions and methods for reparation and prevention of fibrotic lesions

Publications (1)

Publication Number Publication Date
ATE224712T1 true ATE224712T1 (de) 2002-10-15

Family

ID=26738503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916710T ATE224712T1 (de) 1993-05-07 1994-05-09 Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen

Country Status (10)

Country Link
EP (1) EP0702551B1 (de)
JP (1) JPH08510251A (de)
AT (1) ATE224712T1 (de)
AU (1) AU687816B2 (de)
BR (1) BR9406461A (de)
CA (1) CA2161648A1 (de)
DE (1) DE69431433T2 (de)
ES (1) ES2183839T3 (de)
NO (1) NO308507B1 (de)
WO (1) WO1994026249A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
BR9607541A (pt) * 1995-03-03 1997-12-23 Solomon Begelfor Margolin Tratamento de doenças que tem por causa o fator de crescimento da citoquina
JPH11507038A (ja) * 1995-06-07 1999-06-22 ユニヴァースティ オブ サザーン カリフォルニア ５−リポキシゲナーゼ阻害剤を用いる、術後癒着形成を低減又は阻止する方法
DE69927987T2 (de) * 1998-08-13 2006-11-09 Hadasit Medical Research Services & Development Co. Ltd. Hemmung von mit gewebetrauma verbundenen pathogenen prozessen
US6492395B1 (en) 1998-09-18 2002-12-10 Mepha Ag Topical formulation of alkyl-, phenyl-pyridone
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
AU2002347182A1 (en) * 2001-12-18 2003-06-30 Mondobiotech Licensing Out Ag Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
TW200501952A (en) * 2003-02-21 2005-01-16 Shionogi & Co Pirfenidone gel formulations
TW200418516A (en) * 2003-02-21 2004-10-01 Shionogi & Co Droplet dispersed ointment
WO2004089283A2 (en) * 2003-04-04 2004-10-21 Intermune, Inc. Compositions and methods for treating viral infections
CA2545813C (en) 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
MX2007014114A (es) * 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CL2007001597A1 (es) * 2006-06-05 2008-05-16 Novartis Ag Xenon Pharmaceutic Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes
WO2007147297A1 (fr) 2006-06-15 2007-12-27 Shanghai Genomics, Inc. Utilisation de dérivés de pyridone destinés à prévenir et traiter par radioactivité une lésion des poumons
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US9029385B2 (en) 2007-10-26 2015-05-12 Ganesh Raghu Compositions and methods for treating fibroproliferative disorders
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
ES2913095T3 (es) * 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
KR102045723B1 (ko) * 2011-09-14 2019-11-18 시오노기 앤드 컴파니, 리미티드 흡입용 의약 조성물
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP4491180A1 (de) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol-pirfenidon- und pyridonanalogverbindungen und verwendungen davon
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
ZA757570B (en) * 1974-12-09 1977-07-27 Affiliated Med Res A useful n-substituted pyridone
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions

Also Published As

Publication number Publication date
CA2161648A1 (en) 1994-11-24
DE69431433D1 (de) 2002-10-31
JPH08510251A (ja) 1996-10-29
AU687816B2 (en) 1998-03-05
EP0702551A1 (de) 1996-03-27
NO954437D0 (no) 1995-11-06
AU6829194A (en) 1994-12-12
EP0702551A4 (de) 1997-08-20
NO308507B1 (no) 2000-09-25
DE69431433T2 (de) 2003-12-04
BR9406461A (pt) 1996-01-30
ES2183839T3 (es) 2003-04-01
NO954437L (no) 1995-11-06
EP0702551B1 (de) 2002-09-25
WO1994026249A1 (en) 1994-11-24

Similar Documents

Publication Publication Date Title
DE69431433D1 (de) Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen
ATE418986T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems welche einen nicotin-analog und einen acetylcholinesterase inhibitor enthalten
ZA918044B (en) Pyridine and pyridine n-oxide derivatives of diaryl methyl piperidines of piperazines,and compositions and methods of use thereof
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
MY112102A (en) Therapeutic heterocycles.
EP0709375A3 (de) Therapeutisch wirksame Heterocyclen
FI925342A0 (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
TR199802273T2 (xx) Fibrotik lezyonlar�n onar�lmas� ve �nlenmesi.
IE790756L (en) Cerebral therapeutic agent
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
ZA919317B (en) Novel hydroxamic acid and N-hydroxyurea derivatives and their use.
GB9523526D0 (en) Therapeutic compounds
PL309604A1 (en) Pharmaceutical composition for treating nicotin dependence
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
DK0738269T3 (da) Piperidinderivater med PAF-antagonistaktivitet
YU6196A (sh) Transdermalna flasterska formulacija
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
IL141515A (en) Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same
HUT61743A (en) Process for producing 2-(piperidin-1-yl)-ethanol derivatives and pharmaceutical compositions comprising such compounds as active ingredient
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
TR200103144T2 (tr) Yeni bileşikler
IE780217L (en) 1,3,5-triazine-2,6-dione derivatives
BR0017367A (pt) Uso de melagatran ou de um seu derivado farmaceuticamente aceitável, método de tratamento de um distúrbio isquêmico em um paciente tendo, ou sob risco de ter, fibrilação atrial não-valvular, e, formulação farmacêutica
DK0986390T3 (da) Farmaceutiske præparater med cinchosin-dihydrochlorid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee